Last reviewed · How we verify
Skin and soft-tissue infections due to susceptible streptococci
Approved treatments
- Bicillin C-R · Pfizer Inc.
Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Skin and soft-tissue infections due to susceptible streptococci patent landscape — cliff calendar, originator estates, attackable patents
- Skin and soft-tissue infections due to susceptible streptococci treatment landscape brief
- Skin and soft-tissue infections due to susceptible streptococci treatment updates RSS
Frequently asked questions about Skin and soft-tissue infections due to susceptible streptococci
What drugs treat Skin and soft-tissue infections due to susceptible streptococci?
Tracked treatments include Bicillin C-R.
What is the treatment for Skin and soft-tissue infections due to susceptible streptococci?
Standard treatment for Skin and soft-tissue infections due to susceptible streptococci includes Bicillin C-R. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Skin and soft-tissue infections due to susceptible streptococci patent cliff · Skin and soft-tissue infections due to susceptible streptococci CI report
- Treatment: Bicillin C-R · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing